AMAG Pharmaceuticals, Inc. Studies

Ciraparantag is in clinical development as a reversal agent for various anticoagulants including non-vitamin K oral anticoagulants (NOACs). Ciraparantag was previously shown to reverse the anticoagulant effects of edoxaban and enoxaparin, as measured by whole blood clotting time (WBCT).

Video thumbnail

Thank you for registering!

You may now view the resource below.